Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance ; volume:13 ; number:1 ; day:5 ; month:6 ; year:2014 ; pages:1-12 ; date:12.2014
Molecular cancer ; 13, Heft 1 (5.6.2014), 1-12, 12.2014
- Creator
-
Cretella, Daniele
Saccani, Francesca
Quaini, Federico
Frati, Caterina
Lagrasta, Costanza
Bonelli, Mara
Caffarra, Cristina
Cavazzoni, Andrea
Fumarola, Claudia
Galetti, Maricla
La Monica, Silvia
Ampollini, Luca
Tiseo, Marcello
Ardizzoni, Andrea
Petronini, Pier Giorgio
Alfieri, Roberta R.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-4598-13-143
- URN
-
urn:nbn:de:101:1-2021081919350788367985
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cretella, Daniele
- Saccani, Francesca
- Quaini, Federico
- Frati, Caterina
- Lagrasta, Costanza
- Bonelli, Mara
- Caffarra, Cristina
- Cavazzoni, Andrea
- Fumarola, Claudia
- Galetti, Maricla
- La Monica, Silvia
- Ampollini, Luca
- Tiseo, Marcello
- Ardizzoni, Andrea
- Petronini, Pier Giorgio
- Alfieri, Roberta R.
- SpringerLink (Online service)
Other Objects (12)
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Targeting DNAJC19 overcomes tumor growth and lung metastasis in NSCLC by regulating PI3K/AKT signaling
Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating
Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Targeting DNAJC19 overcomes tumor growth and lung metastasis in NSCLC by regulating PI3K/AKT signaling
Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating
Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Targeting DNAJC19 overcomes tumor growth and lung metastasis in NSCLC by regulating PI3K/AKT signaling
Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating
Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells